CD38 and plasma cell myeloma: Phase I study (NCT03314181) combining venetoclax with CD38 antibody daratumumab and dexamethasone demonstrated a high rate of deep and durable responses in patients with relapsed or refractory multiple myeloma, especially for patients with relapsed or refractory multiple myeloma those with t (11;14).662